Siponimod-related bilateral cystoid macular oedema and intravenous fluorescein angiographic findings in a patient with stable proliferative diabetic retinopathy without history of diabetic macular oedema
Document Type
Journal Article
Publication Date
11-11-2022
Journal
BMJ case reports
Volume
15
Issue
11
DOI
10.1136/bcr-2022-251066
Keywords
Drugs: CNS (not psychiatric); Macula; Multiple sclerosis; Retina; Unwanted effects / adverse reactions
Abstract
Siponimod is a sphingosine-1-phosphate receptor modulator used as disease-modifying therapy for relapsing-remitting multiple sclerosis similar to Fingolimod which has been known to cause dose dependent fingolimod associated macular oedema (FAME). We report a case of delayed onset bilateral cystoid macular oedema in a patient with stable proliferative diabetic retinopathy who developed cystoid macular oedema in the setting of siponimod (Mayzent; Novartis Pharmaceuticals; Cambridge, Massachusetts, USA) use. As with FAME, cystoid macular oedema resolved in the patient's eyes with drug cessation and adjunctive topical anti-inflammatory therapy. We highlight unique fluorescein angiographic findings within this class of drugs as well as the clinical challenge posed by comorbid diabetic and inflammatory ophthalmic pathology.
APA Citation
Foos, William F.; Culp, Catherine; Asahi, Masumi; and Patronas, Marena, "Siponimod-related bilateral cystoid macular oedema and intravenous fluorescein angiographic findings in a patient with stable proliferative diabetic retinopathy without history of diabetic macular oedema" (2022). GW Authored Works. Paper 1953.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/1953
Department
Ophthalmology